A randomized, controlled, single-blind trial of leflunomide in the treatment of rheumatoid arthritis

被引：0

作者：

Hu, Yonghong ^{[1
]}

Tu, Shenghao ^{[1
]}

Liu, Peilin ^{[1
]}

机构：

[1] Department of Traditional Chinese Medicine, Huazhong University of Science and Technology, Tongji Hospital, Wuhan 430030, China

来源：

Journal of Huazhong University of Science and Technology - Medical Science | 2001年 / 21卷 / 01期

关键词：

Drug products - Drug therapy - Immunology - Patient treatment - Tissue;

D O I：

10.1007/bf02888043

中图分类号：

学科分类号：

摘要：

The efficacy and safety of leflunomide (LEF) in the treatment of rheumatoid arthritis (RA) were evaluated and the comparison with methotrexate's (MTX's) was performed in a 12-week, single-blind, randomized, parallel trial for treating 81 patients with RA. There were 56 cases in LEF group and 25 cases in MTX group. The dose of LEF was 20 mg per day and MTX 15 mg per week. All patients took oxaproxin simultaneously at the 4th to 6th week after the trail. The results showed that the general effective rate and notable effective rate were 94.64 % and 73.21 % in LEF group, 72 % and 44 % in MTX group, respectively, with the differences being statistically significant between the two groups (P

引用

页码：72 / 74